We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ACRO endorses Foreign Earnings Reinvestment Act

ACRO endorses Foreign Earnings Reinvestment Act

October 12, 2011
CenterWatch Staff

The Association of Clinical Research Organizations (ACRO) supports the Foreign Earnings Reinvestment Act, bipartisan legislation introduced in the U.S. Senate last week by senators Kay Hagan (D-NC) and John McCain (R-AZ).

The legislation would allow American companies to bring overseas earnings back to the U.S. through tax repatriation.

“Clinical research organizations are a prime example of an industry that was founded not long ago with American ingenuity, and where U.S. companies remain among the dominant players globally,” said Doug Peddicord, Ph.D., executive director of ACRO. “Our members have seen revenues and employment more than double over the past 10 years. But disease knows no boundaries and drug development is a global enterprise. As such, our members typically derive at least half of their revenues from outside the U.S.”

North Carolina is a hub for clinical research; ACRO members employ more than 7,000 research professionals in the state. CROs are also significant employers in Arizona, California, Massachusetts, New Jersey, Ohio, Pennsylvania, Virginia, Wisconsin and Texas, among other states.

“This is an issue we have been working on and lobbying on for the better part of this year,” John Lewis, vice president of public affairs for ACRO, told CenterWatch. “By its nature, drug development is global. Our members operate all over the world because that is what is required to run clinical trials and do drug development today.”

“While these numbers are not publicly disclosed,” he said, “as best we can estimate, our members have something in the range of a billion dollars or so of overseas profits that could be brought back to the U.S. and invested.”

Global News CROs/Service Providers Ethics/Regulatory

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing